Antibody-Mediated Rejection Associated With Higher Serum Levels of CXCL13 and CCL21 in Renal Transplant Patients and Altered By Bortezomib/Rituximab Treatment

Trial Profile

Antibody-Mediated Rejection Associated With Higher Serum Levels of CXCL13 and CCL21 in Renal Transplant Patients and Altered By Bortezomib/Rituximab Treatment

Completed
Phase of Trial: Phase IV

Latest Information Update: 19 Aug 2015

At a glance

  • Drugs Bortezomib (Primary) ; Rituximab (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 19 Aug 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top